Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
The blood-brain barrier (BBB) limits the penetration of substances into the brain. Because many drugs, particularly peptides, therefore can not be delivered to the brain, carrier systems were developed to overcome this problem. In earlier studies we demonstrated central analgesic effects of a peptide, dalargin (dal), after systemic administration when this substance was bound onto the surface of polybutylcyanoacrylate nanoparticles and coated with polysorbate 80 but not when it was given alone. The aim of the present study was to investigate the body distribution of 3H-labelled dal bound to nanoparticles compared to unbound dal after i.v. injection in mice. The radioactivity in several tissues, including the brain, was separated in subcellular preparations and was measured after a single i.v. injection over time. Dal radioactivity level in brain preparations was 3 times higher when the drug was bound to nanoparticles whereas the first pass pathway in liver was reduced. The results support previous data that nanoparticles can be used to transport peptides across the BBB.
Schroeder
U
U
Institute of Medical Psychology, Medical Faculty, Otto-v.-Guericke University, Magdeburg, Germany.
Schroeder
H
H
Sabel
B A
BA
D000818:Animals; D001682:Biological Availability; D001812:Blood-Brain Barrier; D004337:Drug Carriers; D004659:Enbucrilate / Q000008:administration & dosage*; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D014018:Tissue Distribution; D014316:Tritium
D004337:Drug Carriers; D014316:Tritium; D016308:Enkephalin, Leucine-2-Alanine; D004659:Enbucrilate; C040996:enkephalin-Leu, Ala(2)-Arg(6)-